Clinical Trials
9 trialsNCT06919965 2026-06-05
MoonRISe-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06770582 2026-06-03
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06388720 2026-05-29
IMGeS
National Cancer Center, Korea
Phase 2 Recruiting
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT07097142 2026-05-04
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT06774131 2026-04-29
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
UroGen Pharma Ltd.
Phase 3 Recruiting
NCT04847063 2026-04-14
Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04779554 2026-04-01
Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC
University of Kentucky
Phase 2 Recruiting
NCT06704191 2026-03-30
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting